MedTech Company Artrya Signs US Partnership to Use AI For Diagnosing Heart Disease - medtigo


MedTech Company Artrya Signs US Partnership to Use AI For Diagnosing Heart Disease

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Artrya, an Australian MedTech company, has announced that its US affiliate has inked a clinical cooperation with Huntsville Heart Center in Alabama. 

According to a press statement, the firms have agreed to study how effective Artrya’s AI technology is at diagnosing coronary heart disease. 

The Artrya Salix is AI-powered software that analyses cardiac CT scans and detects atherosclerotic plaque, a common cause of heart attacks. It assesses a patient’s susceptible plaques, stenosis, calcium score, and total plaque burden in under 15 minutes. 

According to Mobi Health News, the Huntsville Heart Center’s Heart Center Research division will perform multi-scanner retrospective research to validate the AI underpinning Artrya Salix. It will use previously acquired CT images that have been anonymized and uploaded to Salix. Its interpretation will next be compared to that of professional readers selected. 

The heart scans will be compared “to see if we can validate the accuracy of Artrya Salix AI software in diagnosing coronary artery disease, specifically high-risk plaque, as compared to human readers,” according to Dr. Michael L. Ridner the study’s primary investigator. 

“This type of AI technology has the potential to transform the way we practice medicine and, in this case, to save lives. The Heart Center team is ecstatic to be among the first to assess Artrya’s potential, “Dr. Ridner continued. 

The clinical trial will be finished by October this year, according to Artrya USA co-CEOs Jory Tremblay and Ted Schwab. It will provide the validation needed for the eventual commercial deployment of Salix in the United States. 

In partnership with academics from the University of Western Australia, the Harry Perkins Institute of Medical Research, and the Ottawa Heart Institute, Artrya created an AI decision support tool for identifying heart disease. The Australian government’s Medical Research Future Fund contributed A$896,606 (about $700,000) to its development. 

Artrya gained federal government approval to commercialize Salix across the country in October of last year. This year, it collaborated with Envision Medical Imaging, a radiology practice in Perth, to promote the product. 

Leave a Reply